 |
 |
 |
 |
 |
 |
||
 |
 |
 |
 |
 |
| 3 | 1/1 | 返回列表 |
| 查看: 1151 | 回復(fù): 2 | |||
| 本帖產(chǎn)生 1 個(gè) 翻譯EPI ，點(diǎn)擊這里進(jìn)行查看 | |||
[交流]
急求翻譯。多謝�？�。質(zhì)量一般也可以。
|
|||
| The nanoparticles were fabricated using different concentrations of STC (10–35 mM) as a stabilizer. The characterization results of the prepared batches are presented in Table 2. It was observed that the DLE was maximum (98.2%) at 10 mM STC concentration (Batch I), and it decreased drastically with increase in STC concentration. The high DLE achieved was in agreement with the ability of STC to significantly retard solubility of the drug particularly at 10 mM concentration in pH 7.2 (with respect to other surfactant concentrations and the buffer alone), as observed in our earlier study[18]. However, none of the batches with only STC (Batches I–V) as stabilizer were found to be stable as phase separation occurred within 15 days of storage at room temperature (Fig. 1A). In order to achieve a homogenous dispersion, PVA,a polymeric excipient was added to the nanoemulsion. Addition of 1% (w/v) PVA (Batch VI) significantly improved the stability of the nanodispersion, as shown in Fig. 1B. The increased viscosity (from 1.08 cps (Batch I) to 4.3 cps (Batch VI)), by almost four folds, of the nanoemulsion upon addition of PVA may be the factor responsible to prevent the agglomeration by reducing the mobility of the nanoparticles in the dispersion medium. Moreover, PVA being a hydrophilic polymer acts as a coat to shield the particle surface charge responsible to cause their agglomeration [21]. It is probably due to this reason that the nanoparticles were found to be stable despite its low zeta potential. Preparation of a stable nanodispersion in presence of PVA alone (Batch VII) indicates its ability to immobilize nanoparticles by the viscosity imparted by the polymeric solution. However, the DLE of the batch was significantly the lattice arrangement or less ordered crystal lattice of the lipid of Batch V which shows incomplete lipid solidification or the coexistence of its amorphous state. The thermogram of lipid particles of Batches V and VI showed shifted peaks with relatively low heat of enthalpy than that of the pure lipid. This may be due to the presence of drug as a foreign body in the pure lipid and drastic reduction in particle size of lipid which together result in imperfections in the crystal lattice and, therefore, decrease in melting enthalpy. As the quantity of heat required to melt the impure lipid is reduced, a shift in the melting point of the lipid in the nanoparticles is observed. The X-ray diffraction patterns of Batches V and VI along with the pure lipid and drug are presented in Fig. 4(A–D). The XRD results obtained are in good agreement with the results established by DSC measurements. Although, crystalline reflections are visible for SLN of Batch V, the figures demonstrate that the scattering profile exhibited by nanoparticles of Batch VI were of much higher intensity which is again an indication of the existence of lower ordered crystalline state and/or amorphous state of the latter. It can be also observed that after the addition of drug, scattering profile of the lipid remains unchanged, indicating that the lattice order inside the hydrocarbon chains is still conserved. The disappearance of the drug peaks in the formulation shows that the lipid has arrested the re-crystallization of the drug particles from the solvent system upon its evaporation. The investigations related to morphology and solid state characteristics confirm that the crystal structure of the lipid in Batch V has several imperfections and, therefore, exists in a solid liquid transition state or a semisolid state. The inability of the lipid emulsion to recrystallize in presence of Buffer-I may be attributed to partial neutralization of stearic acid in the presence of metallic hydroxide due to which the lipid forms a creamy base and, therefore, fails to regain its solid state in the aqueous medium [22].However, the drug retention ability of the Batches V and VI was independent of the crystal arrangement as no significant difference in their DLE was observed which indicates that the lipid crystals have sufficient space to accommodate the added quantity of drug. The PDI values of Batches VI and VII reveal sufficiently uniform particle size distribution. The comparatively larger PDI of Batch V may be attributed to its physical state, as discussed above, due to which the particles have a tendency of agglomeration and is even to prepare ALN. Approximately, 7–8 ml of the nanodispersion was found to saturate 50 mg of the adsorbent used in each process of each batch. The physiochemical properties of the ALN were evaluated and are presented in Table 3. The drug loading efficiency of the adsorbent was estimated to be 79.8 ± 2.3%. Apart from free drug, the loss during the separation process can also be related to particle size and PDI of the nanoparticles. The improvement in the PDI and relative increase in the average particle size of the re-dispersed nanoparticles relative to that of the nanodispersion indicates that a part of nanoparticles of lower size range were screened and not adsorbed on the adsorbents. This may be due to the fact that the pores of the adsorbents were filled with the nanodispersion and after saturation of these pores; the adsorbent was able to retain nanoparticles of only higher size range trapped in the inter-particulate void space. The above fact was determined by the analysis of the pooled eluent which revealed nano dispersion with 84.5 ± 9.3 nm particle size (PDI = 0.09 ± 0.01). Further drug content analysis on re-dispersion of nanoparticles in aqueous solution containing 1.0% PVA indicated that the re-dispersed amount corresponds to the amount of nanoparticles adsorbed. The photo micrograph of the ALN (Fig. 5) reveals Neusilin particles randomly |
回復(fù)此樓» 猜你喜歡
291求調(diào)劑
已經(jīng)有4人回復(fù)
-
生物學(xué)一志愿985，分?jǐn)?shù)349求調(diào)劑
已經(jīng)有8人回復(fù)
-
328求調(diào)劑，英語六級(jí)551，有科研經(jīng)歷
已經(jīng)有12人回復(fù)
-
070300化學(xué)求調(diào)劑
已經(jīng)有6人回復(fù)
-
考研化學(xué)308分求調(diào)劑
已經(jīng)有7人回復(fù)
-
一志愿上海交大生物與醫(yī)藥專碩324分，求調(diào)劑
已經(jīng)有5人回復(fù)
-
工科0856求調(diào)劑
已經(jīng)有5人回復(fù)
-
一志愿中國石油大學(xué)（華東） 本科齊魯工業(yè)大學(xué)
已經(jīng)有4人回復(fù)
-
279分求調(diào)劑 一志愿211
已經(jīng)有16人回復(fù)
-
求調(diào)劑一志愿武漢理工大學(xué)材料工程（085601）
已經(jīng)有5人回復(fù)
» 搶金幣啦！回帖就可以得到:
-
本子終于提交了。不用再看了，一切閑下來慢慢等。希望一切順利！
+1/632
-
西南交通大學(xué)醫(yī)學(xué)院招收生物醫(yī)學(xué)工程和材料與化工專業(yè)碩士研究生
+1/86
-
國自然面上祈福
+1/85
-
中飛院航空鋰電池團(tuán)隊(duì)接受碩士生調(diào)劑
+1/82
-
中山大學(xué)生醫(yī)工學(xué)院課題組招碩士生（高分子/納米材料/分析傳感/熒光免疫檢測背景）
+2/52
-
南京理工大學(xué)優(yōu)青團(tuán)隊(duì)招聘副教授、博士后、博士、碩士生（化學(xué)、催化方向）
+1/28
-
湖南大學(xué)微生物結(jié)構(gòu)與功能實(shí)驗(yàn)室2026年計(jì)劃招收博士研究生
+1/15
-
誠摯招生（碩士+博士）
+1/12
-
三峽大學(xué) 計(jì)算力學(xué)課題組招收調(diào)劑（力學(xué)/水利/土木/材料/礦業(yè)）
+1/11
-
南開大學(xué)陳樹琪教授研究團(tuán)隊(duì)招收2026級(jí)超構(gòu)材料方向博士研究生
+1/8
-
雙一流天津工業(yè)大學(xué)電信學(xué)院李鴻強(qiáng)教授招收2026年申請審核制博士
+1/7
-
海南師范大學(xué) 孫元元老師團(tuán)隊(duì)招2026級(jí)碩士生2名
+1/7
-
青島科技大學(xué)化工學(xué)院院士團(tuán)隊(duì)2026年擬招收全日制博士研究生1名
+1/6
-
寧波東方理工大學(xué)余鵬課題組2026年上海交大聯(lián)培博士生、博士后、科研助理招聘
+1/6
-
南方科技大學(xué)醫(yī)學(xué)院王鵬課題組博士后招聘
+1/5
-
上海高校交通運(yùn)輸工程專業(yè)環(huán)境方向接收數(shù)一調(diào)劑
+1/4
-
招收化工與材料學(xué)科點(diǎn)研究生
+1/2
-
招收08工學(xué)碩士研究生（名額較多，要求過A區(qū)國家線）
+1/2
-
招收生物與醫(yī)藥（專碩）調(diào)劑生（廣西某高校、B區(qū)）
+1/1
-
溫州醫(yī)科大學(xué)招收特種醫(yī)學(xué)博士研究生1名（專業(yè)不限，有實(shí)驗(yàn)基礎(chǔ)）
+1/1
zerohead
禁蟲 (職業(yè)作家)
- 翻譯EPI: 466
- 應(yīng)助: 1 (幼兒園)
- 貴賓: 0.301
- 金幣: 8727.8
- 帖子: 3768
- 在線: 471.7小時(shí)
- 蟲號(hào): 1041741
|
The nanoparticles were fabricated using different concentrations of STC (10–35 mM) as a stabilizer. The characterization results of the prepared batches are presented in Table 2. It was observed that the DLE was maximum (98.2%) at 10 mM STC concentration (Batch I), and it decreased drastically with increase in STC concentration. 利用不同濃度的STC（10-35mM）作為穩(wěn)定劑，我們成功地合成了納米顆粒。研究結(jié)果表明DLE在STC濃度為10mM的時(shí)候?yàn)樽畲螅?8.2%），而繼后隨著STC的濃度上升而顯著下降。 |
2樓2011-01-09 17:16:29
sltmac
榮譽(yù)版主 (知名作家)
- 翻譯EPI: 161
- 應(yīng)助: 10 (幼兒園)
- 貴賓: 4.557
- 金幣: 29454.8
- 帖子: 5447
- 在線: 633.6小時(shí)
- 蟲號(hào): 996442
★ ★ ★ ★ ★ ★ ★ ★ ★ ★
kaichang(金幣+30, 翻譯EPI+1):謝謝。 2011-01-09 22:21:52
ringzhu(金幣+10):辛苦~~歡迎常來翻譯版~~O(∩_∩)O~ 2011-01-10 11:15:05
kaichang(金幣+30, 翻譯EPI+1):謝謝。 2011-01-09 22:21:52
ringzhu(金幣+10):辛苦~~歡迎常來翻譯版~~O(∩_∩)O~ 2011-01-10 11:15:05
| 該納米粒子用作為穩(wěn)定劑的不同濃度的STC（10-35mM）制備。樣品的表征結(jié)果見表2�？梢钥吹皆赟TC濃度為10mM(釜I)時(shí)DLE達(dá)到最大（98.2%）。隨著STC濃度的繼續(xù)加大，DLE急劇下降。高濃度DLE的制得與我們早期觀察的STC顯著阻礙該藥物在pH7.2、10mM濃度時(shí)的溶解度相吻合（和其它表面活性劑相比）。但是，在室溫儲(chǔ)存15天的時(shí)間內(nèi)，釜I~V沒有發(fā)現(xiàn)一批STC出現(xiàn)穩(wěn)定的相分離（圖1A）。為了達(dá)到均質(zhì)分散的效果，把PVA這樣一種聚合賦形劑加入到納米浮濁液中。釜I添加了1%的PVA可以顯著提高其納米分散液的穩(wěn)定性，如圖1B所示。粘度增加了將近四倍（從釜I的1.08cp增加到釜VI的4.3cp）通過向納米乳濁液中添加PVC可以起到通過減少納米顆粒在分散介質(zhì)中的流動(dòng)性從而阻止顆粒團(tuán)聚的作用。而且PVA作為一種親水聚合物在粒子表面涂膜阻止其團(tuán)聚。可能由于此原因，盡管納米顆粒的電位較低但相對(duì)而言還是比較穩(wěn)定的。在只加PVA的納米分散液（釜VI）表明通過聚合物溶膠的粘度能使納米顆粒固定。該釜里DLE的晶格排列或釜VI的無序晶格排列說明脂類出現(xiàn)固化或同時(shí)存在無定形態(tài)。釜V和釜VI脂類粒子的熱譜分析顯示與純脂類相比有低焓熱同時(shí)顯著減小脂類的粒徑引起晶格的缺陷，因此，引起熔化焓的減小。當(dāng)所需熔化不純脂類的熱值減小時(shí)，觀察到了在納米粒子中脂類熔點(diǎn)的變化。圖4（A-D）為釜V（純脂類）和釜VI（藥類）的XRD圖，XRD結(jié)果與DSC結(jié)果一致。盡管對(duì)釜V的SLN來說其晶型可見，說明了釜VI中納米顆粒的有較高的散射強(qiáng)度再一次說明低有序晶格的存在或者晶格中存在無定形態(tài)。同時(shí)能發(fā)現(xiàn)當(dāng)添加藥物后，脂類的散射圖仍然保持不變，說明C-H鍵仍然保持著。藥物峰的消失說明脂類已經(jīng)使藥物粒子從溶液中由于蒸發(fā)作用發(fā)生重結(jié)晶。形貌表征和固體的性質(zhì)證實(shí)了釜V中脂類晶體結(jié)構(gòu)的幾種缺陷，因此在固液相態(tài)轉(zhuǎn)變的過程中存在著中間態(tài)。添加緩沖劑I的脂類乳濁液不能重結(jié)晶是由于脂類形成奶油狀金屬氫氧化物堿而使硬脂酸部分中和引起的，因此在水介質(zhì)中不能得到其固態(tài)。但釜V和釜VI中藥物的滯留能力與晶格排列的獨(dú)立性有關(guān)，DLE沒有顯著變化說明脂類晶體具有足夠大的空間來儲(chǔ)存加入的藥物。釜VI和VII的PDI值說明粒徑均勻分布，相比較而言釜V的PDI值大一點(diǎn)可以歸因于其物理狀態(tài)。如上所討論，由于在制備ALN時(shí)粒子有團(tuán)聚的趨勢，在每一個(gè)釜的每一步處理過程中，7-8mL納米乳濁液在50mg的吸附劑中達(dá)到飽和，對(duì)ALN生物化學(xué)性質(zhì)的評(píng)價(jià)見表3。吸附劑對(duì)藥物的吸附效率大約為79.8±2.3%。除了游離藥物，分離過程中的損失取決于納米粒子的PDI值。平均粒子尺寸PDI的增大以來于納米乳濁液的再分散，這表明低小尺寸分布的納米粒子不會(huì)被吸附，這可能是由于在孔過飽和后吸附劑的孔和納米乳濁液結(jié)合了；吸附劑只能在寬尺寸的范圍內(nèi)起作用。上述現(xiàn)象可通過洗脫分析證實(shí)，粒徑在84.5±9.3nm之間(PDI = 0.09 ± 0.01).進(jìn)一步對(duì)水中藥物含量的分析可知PVA的含量為1.0%，這表明再分散的量與納米粒子被吸附的量一致。ALN的顯微鏡圖（圖5）揭示了粒子是隨機(jī)分布的。 |
3樓2011-01-09 18:45:05
相關(guān)版塊跳轉(zhuǎn)
我要訂閱樓主 kaichang 的主題更新
| 3 | 1/1 | 返回列表 |
| 最具人氣熱帖推薦 [查看全部] | 作者 | 回/看 | 最后發(fā)表 | |
|---|---|---|---|---|
|
[考研]
 材料與化工考研調(diào)劑
+4
|
孅華 2026-03-22 | 4/200 |
|
|---|---|---|---|---|
|
[考研] 328求調(diào)劑 +4 | LHHL66 2026-03-23 | 4/200 |
|
|
|
[考研]
 0854 考研調(diào)劑 招生了！AI 方向
+3
|
pk3725069 2026-03-19 | 14/700 |
|
|
|
[考研] 306求0703調(diào)劑一志愿華中師范 +6 | 紙魚ly 2026-03-21 | 6/300 |
|
|
|
[考研] 307求調(diào)劑 +3 | 余意卿 2026-03-21 | 3/150 |
|
|
|
[考研] 289求調(diào)劑 +7 | 懷瑾握瑜l 2026-03-20 | 7/350 |
|
|
|
[考研] 求調(diào)劑 +5 | Zhangbod 2026-03-21 | 7/350 |
|
|
|
[考研] 一志愿華中科技大學(xué)071000，求調(diào)劑 +4 | 沿岸有貝殼6 2026-03-21 | 4/200 |
|
|
|
[考研] 311求調(diào)劑 +3 | 勇敢的小吳 2026-03-20 | 3/150 |
|
|
|
[考研] 307求調(diào)劑 +3 | 余意卿 2026-03-18 | 3/150 |
|
|
|
[考研] 265求調(diào)劑 +3 | Jack?k?y 2026-03-17 | 3/150 |
|
|
|
[考研] 265求調(diào)劑 +9 | 梁梁校校 2026-03-17 | 9/450 |
|
|
|
[考研] 085700資源與環(huán)境308求調(diào)劑 +12 | 墨墨漠 2026-03-18 | 13/650 |
|
|
|
[考研] 一志愿重慶大學(xué)085700資源與環(huán)境專碩，總分308求調(diào)劑 +3 | 墨墨漠 2026-03-18 | 3/150 |
|
|
|
[考研] 294求調(diào)劑材料與化工專碩 +15 | 陌の森林 2026-03-18 | 15/750 |
|
|
|
[考研] 求調(diào)劑一志愿南京航空航天大學(xué)289分 +3 | @taotao 2026-03-19 | 3/150 |
|
|
|
[考研] 一志愿西安交通大學(xué) 學(xué)碩 354求調(diào)劑211或者雙一流 +3 | 我想要讀研究生 2026-03-20 | 3/150 |
|
|
|
[考研] 261求B區(qū)調(diào)劑，科研經(jīng)歷豐富 +3 | 牛奶很忙 2026-03-20 | 4/200 |
|
|
|
[考研]
320求調(diào)劑0856
+3
|
不想起名字112 2026-03-19 | 3/150 |
|
|
|
[考研] 085600材料與化工調(diào)劑 324分 +10 | llllkkkhh 2026-03-18 | 12/600 |
|